Literature DB >> 8665033

Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract.

S A Kharitonov1, K F Chung, D Evans, B J O'Connor, P J Barnes.   

Abstract

Nitric oxide (NO) is detectable in the exhaled air of human subjects, and its concentration is increased in patients with asthma. We have investigated the origin of the increase in exhaled NO in asthmatic patients by using different expiratory maneuvers and by direct sampling from the upper and lower respiratory tracts. Exhaled NO was measured by a chemiluminescence analyzer. Concentrations of NO measured during expiration against the resistance of the analyzer with exhaled flow of 1 L/min, were 78 +/- 3 ppb in normal subjects (n = 46) and significantly elevated in patients with asthma (301 +/- 26 ppb, n = 30, p < 0.001). Values of exhaled NO were lower when measured during unobstructed expiration with a flow of 5 L/min with sampling from a side-arm (7 +/- 1 ppb), but again were elevated in patients with asthma (46 +/- 6 ppb, p < 0.001). Breath-holding for 20 s resulted in an initial peak of NO, but end-expiration values similar to the unobstructed expiration. The concentration of NO in the nose was considerably greater than in expired air (996 +/- 39 ppb) and was elevated in patients with asthma (1,390 +/- 71 ppb, p < 0.002). Direct sampling from trachea and right middle lobe bronchus via a fiberoptic bronchoscope gave similar values in five normal and 15 asthmatic subjects to the values recorded during unobstructed expiration, and there was a good correlation between values in expired air and direct sampling (trachea r = 0.91, right middle lobe r = 0.87, p < 0.001). We conclude that exhaled NO measured in an unobstructed breath reflects concentrations in the lower respiratory tract, but that breath-holding or expiration against resistance is contaminated by residual NO derived from the upper respiratory tract. We also provide evidence that the elevated levels of exhaled NO in asthmatic patients are derived predominantly from the lower respiratory tract.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8665033     DOI: 10.1164/ajrccm.153.6.8665033

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  44 in total

Review 1.  Exhaled nitric oxide during exercise.

Authors:  A W Sheel; J Road; D C McKenzie
Journal:  Sports Med       Date:  1999-08       Impact factor: 11.136

2.  Dissociation between exhaled nitric oxide and hyperresponsiveness in children with mild intermittent asthma.

Authors:  M Silvestri; D Spallarossa; E Battistini; V Brusasco; G A Rossi
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

3.  Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breath holding.

Authors:  S A Kharitonov; P J Barnes
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

4.  Reduction in exhaled nitric oxide immediately after methacholine challenge in asthmatic children.

Authors:  G L Piacentini; A Bodini; D G Peroni; M Miraglia del Giudice; S Costella; A L Boner
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

5.  Exhalation flow and pressure-controlled reservoir collection of exhaled nitric oxide for remote and delayed analysis.

Authors:  P Paredi; S Loukides; S Ward; D Cramer; M Spicer; S A Kharitonov; P J Barnes
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

6.  Exhaled nitric oxide levels during treatment of pediatric acute asthma exacerbations and association with the need for hospitalization.

Authors:  Kyle A Nelson; Pearlene Lee; Kathryn Trinkaus; Robert C Strunk
Journal:  Pediatr Emerg Care       Date:  2011-04       Impact factor: 1.454

Review 7.  Exhaled nitric oxide in the diagnosis and management of asthma: clinical implications.

Authors:  G W Rodway; J Choi; L A Hoffman; J M Sethi
Journal:  Chron Respir Dis       Date:  2009       Impact factor: 2.444

8.  Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress.

Authors:  I Horváth; L E Donnelly; A Kiss; P Paredi; S A Kharitonov; P J Barnes
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

9.  Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype.

Authors:  Erika J Sims; Catherine M Jackson; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

10.  Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma.

Authors:  Graeme P Currie; Suvi Stenback; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.